The OncoRat provides unique advantages over mouse models for conducting in vivo efficacy evaluation of potential cancer therapies. Better engraftment rates in the OncoRat result in a wider variety of tumor biology. Other advantages include larger tumor, blood and tissue samples for biomarker and downstream analysis as well as a better model for ADME, PK/PD and toxicology.

Hera can consult with your team to select the most appropriate tumor model. Your molecule can be profiled in a variety of tumor models and compared or combined to standards of care for combination studies and IND filing.

If your model of interest is not listed below it can be established in the OncoRat. Model establishment is typically much faster than in mouse, in particular for PDX models due to the larger tumor growth.

Tumor ModelRat EngraftmentIdeal for:
VCaP Prostate80-100%AR resistance, castration resistant studies
VCaP MDVR Prostate90-100%Anti-androgen drug resistance studies, castration resistant studies
LNCaP Prostate90-100%AR sensitivity
H358 NSCLC100%KRAS mutation studies, EGFR - KRAS - BRAF - MEK - ERK signaling
MCF-7 Breast100%ER+ breast cancer, CDK 4/6 inhibition, early and advanced tumor development, anti-estrogen therapies.
HCC1954 Breast100%HER2+ studies, ER- studies, AR inhibitors
HCT116 colon75-100%Tumorigenesis, colorectal cancer metastasis, CDK inhibition, TGFβ +
MIA PaCa-2 pancreatic100%KRAS, epithelial-to-mesenchymal transition (EMT), circulating tumor markers, radiolabeled nucleotide therapy
OCI-AML2 leukemia100%NOS and VEGF signaling, angiogenesis inhibitors, DNA methylation studies
786-O renal cell carcinoma100%VEGF inhibition studies, bone metastasis development, hypoxia and tumor progression